Last reviewed · How we verify
Neoadjuvant chemotherapy + Interval Debulking Surgery
Neoadjuvant chemotherapy shrinks ovarian tumors before surgical removal, followed by interval debulking surgery to resect remaining disease.
Neoadjuvant chemotherapy shrinks ovarian tumors before surgical removal, followed by interval debulking surgery to resect remaining disease. Used for Advanced ovarian cancer (Stage III-IV) unsuitable for primary cytoreduction.
At a glance
| Generic name | Neoadjuvant chemotherapy + Interval Debulking Surgery |
|---|---|
| Sponsor | Catholic University of the Sacred Heart |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This is a combined treatment approach where chemotherapy is administered first to reduce tumor burden and improve resectability, followed by surgical cytoreduction after a treatment interval. The chemotherapy sensitizes tumors and reduces their size, allowing surgeons to achieve more complete tumor removal during the subsequent debulking procedure, which aims to maximize overall survival in advanced ovarian cancer.
Approved indications
- Advanced ovarian cancer (Stage III-IV) unsuitable for primary cytoreduction
Common side effects
- Myelosuppression
- Nausea and vomiting
- Peripheral neuropathy
- Alopecia
- Surgical complications
Key clinical trials
- A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery (PHASE2)
- Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer (NA)
- Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer (PHASE2)
- Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer (NA)
- NeoAdjuvant ChemoTherapy With KELIM Guided Interval vs. Delayed Interval Debulking Surgery (NA)
- Prognostic Value of (DHODH) Expression in (HGSOC): A Comparative Study Between Neoadjuvant and Adjuvant Chemotherapy Settings
- Using Aspirin to Improve Immunological Features of Ovarian Tumors (EARLY_PHASE1)
- A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: